The Binding of CD93 to Multimerin-2 Promotes Choroidal Neovascularization.
Angiogenesis Inhibitors
/ immunology
Animals
Antigens, Surface
/ metabolism
Choroid
/ blood supply
Choroidal Neovascularization
/ metabolism
Endothelial Cells
/ metabolism
Extracellular Matrix Proteins
/ metabolism
Humans
Intercellular Signaling Peptides and Proteins
/ metabolism
Macular Degeneration
/ metabolism
Membrane Glycoproteins
/ metabolism
Mice
Mice, Knockout
Models, Biological
Receptors, Complement
/ metabolism
Journal
Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701
Informations de publication
Date de publication:
01 07 2020
01 07 2020
Historique:
entrez:
23
7
2020
pubmed:
23
7
2020
medline:
2
1
2021
Statut:
ppublish
Résumé
The purpose of this study was to investigate the involvement of CD93 and Multimerin-2 in three choroidal neovascularization (CNV) models and to evaluate their contribution in the neovascular progression of age-related macular degeneration (AMD). Choroidal neovascular membranes collected during surgery from AMD patients were analyzed by microscopy methods. Laser-induced CNV mouse models and choroid sprouting assays (CSAs) were carried out using the CD93 knockout mouse model. An original ex vivo CSA of vascular angiogenesis, employing choroid tissues isolated from human donors, was developed. In contrast to healthy choroid endothelium, hyperproliferative choroidal endothelial cells (ECs) of AMD patients expressed high levels of CD93, and Multimerin-2 was abundantly deposited along the choroidal neovasculature. CD93 knockout mice showed a significant reduced neovascularization after laser photocoagulation, and their choroidal ECs displayed a decreased ability to produce sprouts in ex vivo angiogenesis assays. Moreover, the presence of an antibody able to hamper the CD93/Multimerin-2 interaction reduced vascular sprouting in the human CSA. Our results demonstrate that CD93 and its interaction with Multimerin-2 play an important role in pathological vascularization of the choroid, disclosing new possibilities for therapeutic intervention to neovascular AMD.
Identifiants
pubmed: 32697305
pii: 2770354
doi: 10.1167/iovs.61.8.30
pmc: PMC7425738
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Antigens, Surface
0
EMILIN3 protein, human
0
Extracellular Matrix Proteins
0
Intercellular Signaling Peptides and Proteins
0
Membrane Glycoproteins
0
Mmrn2 protein, mouse
0
Receptors, Complement
0
complement 1q receptor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
30Références
Matrix Biol. 2020 May;87:11-25
pubmed: 31422156
Oncotarget. 2016 Jan 12;7(2):2022-37
pubmed: 26655500
Graefes Arch Clin Exp Ophthalmol. 2009 Feb;247(2):171-7
pubmed: 18781316
Mol Vis. 2011;17:3566-73
pubmed: 22219652
Biochem Biophys Res Commun. 2016 Aug 5;476(4):467-474
pubmed: 27255994
Cancer Cell. 2013 Aug 12;24(2):229-41
pubmed: 23871637
Physiol Rev. 2018 Jan 1;98(1):3-58
pubmed: 29167330
Sci Transl Med. 2018 Oct 17;10(463):
pubmed: 30333240
Int J Mol Sci. 2018 Dec 11;19(12):
pubmed: 30544909
Cell Mol Life Sci. 2020 Mar;77(5):819-833
pubmed: 31893312
N Engl J Med. 2008 Jun 12;358(24):2606-17
pubmed: 18550876
Int J Colorectal Dis. 2015 Jul;30(7):883-90
pubmed: 26008729
Cochrane Database Syst Rev. 2019 Mar 04;3:CD005139
pubmed: 30834517
Nat Protoc. 2013 Nov;8(11):2197-211
pubmed: 24136346
Oncotarget. 2014 May 15;5(9):2750-60
pubmed: 24809468
Cell Commun Signal. 2019 May 28;17(1):55
pubmed: 31138217
Lab Anim (NY). 2011 May;40(5):155-60
pubmed: 21508954
Cancer Res. 2015 Nov 1;75(21):4504-16
pubmed: 26363010
Nat Commun. 2019 Jul 26;10(1):3347
pubmed: 31350409
PLoS One. 2013 Jul 26;8(7):e69552
pubmed: 23922736
Matrix Biol. 2017 Dec;64:112-127
pubmed: 28912033
Oncogene. 2017 Nov 2;36(44):6097-6108
pubmed: 28671670
FEBS Lett. 2008 Jul 23;582(17):2542-8
pubmed: 18582465
Oncogene. 2012 Jun 28;31(26):3136-47
pubmed: 22020326
Oncotarget. 2016 Mar 1;7(9):10090-103
pubmed: 26848865
Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):722-730
pubmed: 29392318
J Immunol. 2004 Mar 15;172(6):3406-14
pubmed: 15004139
Sci Rep. 2018 May 23;8(1):8053
pubmed: 29795291
Immunology. 2005 May;115(1):63-73
pubmed: 15819698
Mol Aspects Med. 2012 Aug;33(4):487-509
pubmed: 22705444
Lancet Glob Health. 2014 Feb;2(2):e106-16
pubmed: 25104651
Histochem Cell Biol. 2012 Sep;138(3):419-33
pubmed: 22644377
Mol Cell Proteomics. 2013 Dec;12(12):3599-611
pubmed: 23979707
J Clin Invest. 2018 Aug 1;128(8):3280-3297
pubmed: 29763414
J Cell Physiol. 2017 Jul;232(7):1767-1773
pubmed: 27859225
Am J Physiol Regul Integr Comp Physiol. 2002 Aug;283(2):R281-3
pubmed: 12121837
FEBS J. 2019 Sep;286(17):3299-3332
pubmed: 31287944
Ophthalmology. 2009 Oct;116(10 Suppl):S1-7
pubmed: 19800534
Lancet. 2008 Nov 22;372(9652):1835-45
pubmed: 19027484
Lancet Glob Health. 2017 Dec;5(12):e1221-e1234
pubmed: 29032195